Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, being the third leading cause of cancer-related death worldwide, with approximately 745 000 deaths reported annually. For advanced patients, including patients with tumoral portal vein thrombosis (PVT), most treatment guidelines recommend systemic therapy, either combination immunotherapy (IO) or combination of immunotherapy and anti-angiogenic treatment for first line option. Results for PVT patients are provided in one trial with a median overall survival of 14.2 months with IO underlying the necessity to improve treat

Trial Details

NCT ID
NCT07122089
Phase
PHASE2
Sponsor
Center Eugene Marquis
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • Selective Internal Radiotherapy
  • Tremelimumab
  • Durvalumab
Locations (sample)
  • Grenoble, France|45.17869,5.71479
  • Lille, France|50.63391,3.05512
  • Marseille, France|43.29695,5.38107
  • Montpellier, France|43.61093,3.87635
  • Nice, France|43.70313,7.26608

Key Eligibility Criteria

  • ECOG Performance Status 0-1,
  • Histologically proven HCC or noninvasive HCC diagnosis according to LiRADS criteria,
  • HCC with Portal vein involvement (PVT), segmental, sectorial or lobar, evaluated by diagnostic imaging (CT scan or MRI),
  • At least one measurable lesion≥ 10mm using mRECIST criteria evaluated by diagnostic imaging,

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →